INmune Bio Inc. (INMB)
INMB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/0001213900-26-036370-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INMB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001711754 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $50K |
| Net income | -$45.9M |
| Operating income | -$47.4M |
| Net margin | -91866.0% |
| Operating margin | -94766.0% |
| Revenue growth | +257.1% |
| Cash | $24.8M |
| Total assets | $32.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 586.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. 6 In response to these conditions, management is currently evaluating different strategies to obtain the required funding of future operations." | 10-Q 2026-11-05 |
| Cash and burn | $16.3M cash; operating cash flow -$3.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 30,959,079 (2026-11-05); 26,585,258 a year earlier; 18,021,692 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-10-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.7M | -$3.4M | $16.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$1.3M | -$3.2M | $18.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$5.4M | -$3.4M | $21.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | $0 | -$5.3M | -$2.9M | $24.8M | No debt tags | $50K | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $0 | -$6.5M | -$5.4M | $27.7M | No debt tags | $50K | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $0 | -$24.5M | -$7.4M | $33.4M | $15.0M | $50K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $50K | -$9.7M | -$6.8M | $19.3M | $15.0M | $50K | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$9.2M | -$11.0M | $20.9M | $15.0M | $14K | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-10-29 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-30 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-05 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-29 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 602 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.1% |
| 1 month | -37.5% |
| 3 months | -49.5% |
| Year to date | -32.7% |
| 1 year | -26.6% |
| From 52-week high | -58.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
| SAEN | Genenta Science S.p.A. | $0.6000 | -7.66% | $28.9M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| PTHS | Pelthos Therapeutics Inc. | $7.15 | -3.90% | $28.1M |
| MGX | Metagenomi Therapeutics Inc. | $0.6800 | -1.69% | $25.7M |
| EVAX | Evaxion A/S American Depositary Share | $2.77 | +0.54% | $25.5M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier